Redcare Pharmacy N.v. · XETR:RDC
Redcare Pharmacy — Q1 2024 Earnings Presentation
21 slides from Redcare Pharmacy's earnings presentation, Apr 25, 2024
Slide 1: Q1 2024 Earnings call presentation
¥ Redcare Qi 2024 Earnings call presentation. @SEVENUM! 25 APRIL 2024 _ +)
Slide 2: Presenting live from our headquarters
»*: Presenting live from our headquarters.
Slide 3: Today's presenters
Today’s presenters. Olaf Heinrich, Jasper Eenhorst, Chief Executive Officer. Chief Financial Officer.
Slide 4: Today's agenda
Today’s agenda. Ci) Financial performance. C2) Update on business and strategy. 3) Outlook and guidance. I]
Slide 5: Financial performance
Financial performance.
Slide 6: Q1 2024 highlights
@ FINANCIAL PERFORMANCE Qi 2024 highlights. > Fast total and organic growth. Total sales up 51% in Qi 2024, excluding MediService 19%. > Non-Rx growth of 20%. +17% in the DACH Segment and +29% in the International Segment. > Adj. EBITDA margin above 2% (2.1%) with increase in Rx marketing spend. Adj
Slide 7: Fast growth in both segments continued
Fast growth in both segments continued. Total DACH International +50.6% Ce EUR 107M EUR 372M Qi 2023 Qi 2024 Qi 2023 Qi 2024 Qi 2023 Qi 2024
Slide 8: Active customers +1.5M, constantly high NPS
Active customers +1.5M, constantly high NPS. Number of customers (NPs) & 7 +0.4M Net Promoter Score +0.3M Qi 2024 (ai 2023: 71) +0.4M 11.2M +0.4M 7 oo 9.7M +1.5M € 58.92 Average Shopping Basket Value Mar 2023 Mar 2024 Qi 2024 (ai 2023: 57.93) I]
Slide 9: Fast increase of orders; averaging nearly 100k per day
Fast increase of orders; averaging nearly 100k per day. en Number of orders are of repeat orders TT in percentage of total in millions 87% y 81% 83% 85% 84% 81% 82% 83% 81% (ert Q2 Q3 a4 at Q2 Q3 a4 fers 2021 2022 2023 2024 Orders: sales to end-customers / patients (B2C) both own-stock and platform
Slide 10: Key Financials | Profit & Loss
@ KEY FINANCIALS | PROFIT & LOSS ) Adj. EBITDA margin of 2.1% or EUR 12M. MediService included since mid-Q2 2023. in millions of euros, adjusted numbers Sales Gross profit margin Selling & distribution margin Administrative cost margin Adj. EBITDA margin Adj. EBITDA EBITDA Quarter-over-Quarter Q4 20
Slide 11: Key Financials | Gross Profit Margin
@ KEY FINANCIALS | GROSS PROFIT MARGIN ) Underlying gross margin up 0.3 pp vs. Qi last year. Adjusted gross profit margin Adjusted gross profit margin in percentage of sales in percentage of sales 23.4% 27.7% 22.8% Qi 2023 Qi 2024 Qi 2024 Q4 2023 Qi 2024 excluding including MediService MediService 1
Slide 12: Key Financials | Selling, Distribution and Admin Ratio
@ KEY FINANCIALS | SELLING, DISTRIBUTION AND ADMIN RATIO ) Cost inflation and e-Rx marketing largely offset by efficiencies. Adjusted SD&A costs Adjusted SD&A costs in percentage of sales in percentage of sales (21.3%) (25.4%) (Based) (19.8%) (21.3%) Qi 2023 Qt 2024 Qt 2024 Cees) Gi 2024 excluding i
Slide 13: Key Financials: Cash Flow
KEY FINANCIALS: CASH FLOW Cash flow EUR +15M, benefiting from seasonality. Cash flow in millions of euros ait 17 (9) (4) 219 204 31 Dec 2023 31 Mar 2024 Cash and Operating result Working capital* Investments* Financing and Cash and short-term adjusted for movements foreign short-term financial asset
Slide 14: Update on business and strategy
Update on business and strategy.
Slide 15: Redcare's eHealth-CardLink solution
Redcare’s eHealth-CardLink solution: The best way to redeem e-scripts fully digitally. Redcare’s solution approved by gematik on 23 April 2024. CardLink solution active for patients within the Shop Apotheke app by early May. Patients will benefit from this most convenient redemption method via CardL
Slide 16: Status quo on eHealth-CardLink
@ BUSINESS AND STRATEGY Status quo on eHealth-CardLink. 14TH MARCH 2024 19T4MARCH 2024 230 APRIL 2024 gematik’s shareholders Final release of Final approval of meeting approved the specifications by Redcare’s solution. final technical gematik. specification for eH-CL. > STARTING MARCH 2024 > EARLY M
Slide 17: Our fully digital customer journey for e-Rx
BUSINESS AND STRATEGY Our fully digital customer journey for e-Rx. Endlich da: Das E-Rezept. Mo. - Fr. bie 18 Uhr oder Sa, bis 12 Une bestellt, am naichsten Werktag geliefert* Bonus sichern! Weitere Artivol versandkostentrel* 0 Funktion Welches Rezept machten Sie einlosen? Das E-Rezept ist auf meine
Slide 18: Outlook and guidance
Outlook and guidance.
Slide 19: Guidance for full-year 2024
@ FINANCIAL OUTLOOK AND GUIDANCE 2024 _) Guidance for full-year 2024. > Total sales to increase to EUR 2.3-2.5 billion, a growth of 30-40%. > Non-Rx sales growth 15-25%. >» MediService expected to grow by mid-single digits. > Adj. EBITDA margin 2% to 4%. @ Mid- to longer-term guidance of adjusted EB
Slide 20: Questions
¥ Redcare questions. ask
Slide 21: Thank you
Thank you. @SEVENUM I 25 APRIL 2024 _ ) ¥ Redcare